An Evaluation of the Hemizygous Transgenic Tg.AC Mouse for Carcinogenicity Testing of Pharmaceuticals. I. Evidence for a Confounding Nonresponder Phenotype
Free accessResearch articleFirst published online July, 1998
An Evaluation of the Hemizygous Transgenic Tg.AC Mouse for Carcinogenicity Testing of Pharmaceuticals. I. Evidence for a Confounding Nonresponder Phenotype
We have completed 2 26-wk studies to evaluate the hemizygous transgenic Tg.AC mouse, which has been proposed as an alternative short term model for testing carcinogenicity. We attempted to evaluate the response to the known rodent carcinogens cyclophosphamide, phenolphthalein, and tamoxifen and to the noncarcinogen chlorpheniramine following topical application. In the first study, a weak response (2/17 animals) was observed to the positive control 12-O-tetradecanoylphorbol 13-acetate (TPA in ethanol, 1.25 μg), and no response was observed to cyclophosphamide, phenolphthalein, or chlorpheniramine, despite evidence for skin penetration. The second study compared 1.25 μg and 6.25 μg of TPA in ethanol and acetone solutions. Tamoxifen was also evaluated in both solvents and orally. No significant response was observed to tamoxifen by skin paint or oral routes. Over 60% of the high dose TPA-treated animals showed no (0 or 1) papilloma response, and 30% of the animals each developed more than 32 papillomas. The heterogenous response to high dose TPA may be related to variability in the responsiveness of hemizygous animals. In light of these findings, further Tg.AC studies should employ homozygous animals, and the underlying cause for heterogeneity in the tumorigenic response of Tg.AC mice should be identified and eliminated.
1. Anderson LAV, Ludeman SM, Colvin OM, Grochow LB, and Strong JM (1995). Quantitation of 4-hydroxycycIophosphamide/aldophos-phamide, an activated metabolite of cyclophosphamide. J. Chro-matogr. B Biomed.. 667: 247–257.
2.
2. Cannon RE, Spalding JW, Trempus CS, Szczesniak CJ, Virgil KM, Humble MC, and Tennant RW (1997). Kinetics of wound-induced v-Ha-ras transgene expression and papilloma development in transgenic Tg.AC mice. Mol. Carcinog.. 20: 108–114.
3.
3. Contrera JF, Jacobs AC, and DeGeorge JJ (1997). Carcinogenicity testing and the evaluation of regulatory requirements for pharmaceuticals. Regul. Toxicol. Pharmacol.. 25: 130–145.
4.
4. Dunnick JK, Hardisty JF, Herbert RA, Seely JC, Furedi-Machacek EM, Foley JF, Lacks GJ, Staslewicz JE, and French JE (1997). Phenophthalein rapidly induces malignant hematopoietic tumors and loss of heterozygosity in p53 wild type allele in heterozygous p53 deficient mice. Toxicol. Pathol.. 25: 533–540.
5.
5. Federal Register (1996). Testing for Carcinogenicity of Pharmaceuticals. No. 43298, August 21, 1996.
6.
6. Fornander T, Hellstrom AC, and Moberger B (1993). Descriptive clinicopathologic study of 17 patients with endometrial cancer during or after adjuvant tamoxifen in early breast cancer. J. Natl. Cancer Inst.. 85: 1850–1855.
7.
7. Friedman OM, Myles A, and Colvin M (1979). Cyclophosphamide and related phorphoramide mustards, current status and future prospects. Adv. Cancer Chemother.. 1: 143–204.
8.
8. Han X and Liehr JG (1992). Induction of covalent DNA adducts in rodents by tamoxifen. Cancer Res.. 52: 1360–1363.
9.
9. Hansen LA, Spalding JW, French JE, and Tennant RW (1995). A transgenic mouse model (Tg.AC) for skin carcinogenesis: Inducible transgene expression as a second critical event. Prog. Clin. Biol. Res.. 391: 223–235.
10.
10. Hansen LA and Tennant RW (1994). Follicular origin of epidermal papillomas in v-Ha-ras transgenic Tg.AC mouse skin. Proc. Natl. Acad. Sci. USA. 91: 7822–7826.
11.
11. Hard GC, Iatropoulos MJ, Jordan K, Radi L, Kaltenberg OP, Imondi AR, and Williams GM (1993). Major difference in the hepatocar-cinogenicity and DNA adduct forming ability between toremifene and tamoxifen in female Crl:CD(BR) rats. Cancer Res.. 53: 4534–4541.
12.
12. Kedar RP, Bourne TH, Powles TJ, Collins WP, Ashley SE, Cosgrove DO, and Campbell S (1994). Effects of tamoxifen on uterus and ovaries of postmenopausal women in a randomized breast cancer prevention trial. Lancet. 343: 1318–1321.
13.
13. Leder A, Kuo A, Cardiff RD, Sinn E, and Leder P (1990). v-Ha-ras transgene abrogates the initiation step in mouse skin tumorigenesis: Effects of phorbol esters and retinoic acid. Proc. Natl. Acad. Sci. USA. 87: 9178–9182.
14.
14. Lim CK, Yuan ZK, Lamb JH, White INH, De Matteis F, and Smith LL (1994). A comparative study of tamoxifen metabolism in female rat, mouse and human liver microsomes. Carcinogenesis. 15: 589–593.
15.
15. Marquardt P (1970). Experimentell Untcrsuchungen über carcinogene wirkungen von Krebs-chemotherapeutica un immunosuppres-siva. Amz. Fors.. 20: 1461–1467.
16.
16. Matsuyama M, Maekawa A, and Nakamura T (1966). Biological studies of anticancer agents. II. Effect of percutaneous applications. GANN. 57: 295–298.
17.
17. Matthews EJ, Spalding JW, and Tennant RW (1993). Transformation of BALB/c-3T3 cells: V. Transformation responses of 168 chemicals compared with mutagenicity in salmonella and carcinogenicity in rodent bioassays. Environ. Health Perspect.101(suppl. 2): 347–482.
18.
18. National Toxicology Program (1986). Toxicology and Carcinoge-neisis Studies of Chlorpheniramine Maleate (CAS No. 113-92-8) in F344/n Rats and B6C3F1 Mice (Gavage Studies). Technical Report Series No. 317, National Institute for Environmental Health Sciences, Research Triangle Park, North Carolina.
19.
19. National Toxicology Program (1996). Toxicology and Carcinogenesis Studies of Phenolphthalein (CAS No. 77-09-8) in F344M Rats and B6C3F1 Mice (Feed Studies). Technical Report Series No. 465, National Institute for Environmental Health Sciences, Research Triangle Park, North Carolina.
20.
20. Shimkin MB, Weisburger JH, Weisbcrger EK, Gubareff N, and Suntzeff V (1966). Bioassay of 29 alkylating chemicals by the pulmonary-tumor response in strain A mice. J. Natl. Cancer Inst.. 36: 915–935.
21.
21. Silva EG, Tomos CS, and Follen-Mitchell M (1994). Malignant neoplasms of the uterine corpus in patients treated for breast cancer: The effect of tamoxifen. Int. J. Gynecol. Pathol.. 13: 248–258.
22.
22. Sistare FD, Anderson L, Contrera JF, Cordaro JC, Ellison C, Faus-tino P, Grieshaber CK, Long-Bradley P, Matthews E, Prasanna HR, Rosenzweig B, Strong J, Thompson K, and Weaver JL (1997). A preliminary evaluation of the Tg.AC transgenic mouse model for carcinogenicity testing. In: Molecular Toxicology: Utilization in Accelerated Drug Discovery and Chemical Safety Analysis, P. Guttry (ed). IBC Library Series, International Business Communications, Southbridge, Massachusetts, pp. 39–60.
23.
23. Slaga TJ and Fischer SM (1983). Strain differences and solvent effects in mouse skin carcinogenesis experiments using carcinogens, tumor initiators and promoters. Prog. Exp. Tumor Res.. 26: 85–109.
24.
24. Spalding JW, Momma J, El well MR, and Tennant RW (1993). Chemically induced skin carcinogenesis in a transgenic mouse line (Tg.AC) carrying a v-Ha-ras gene. Carcinogenesis. 14: 1335–1341.
25.
25. Tennant RW, French JE, and Spalding JW (1995). Identifying chemical carcinogens and assessing potential risk in short-term bioassays using transgenic mouse models. Environ. Health Perspect.. 103: 942–950.
26.
26. Tennant RW, Spalding J, and French JE (1996). Evaluation of transgenic mouse bioassays for identifying carcinogens and noncarcinogens. Mutat. Res.. 365: 119–127.
27.
27. Thompson KL, Rosenzweig BA, and Sistare FD (1998). An evaluation of the hemizygous transgenic Tg.AC mouse for carcinogenicity testing of pharmaceuticals. II. A genotypic marker that predicts tumorigenic responsivness. Toxicol. Pathol.26: 548–555 (this issue).
28.
28. Tucker MJ, Adam HK, and Patterson JS (1984). Tamoxifen. In: Safety Testing of New Drugs. Laboratory Predictions and Clinical Performance, DR Laurence, AEM McLean, and M Weatherall (eds). Academic Press, London, pp. 125–161.
29.
29. U.S. Pharmacopeia (1995). USP 23. The National Formulary NF 18.The United States Pharmacopeial Convention, Rockville, Maryland, p. 1205.
30.
30. Van Leeuwen FE, Benraadt TJ, Coebergh JWW, Kiemeney LA, Gimbrere CH, Otter R, Schouten LI, Damhuis RA, Bontenbal M, and Diepenhorst FW (1994). Risk of endometrial cancer after tamoxifen treatment of breast cancer. Lancet. 343: 1318–1321.
31.
31. Walker SE and Anver MR (1979). Accelerated appearance of neoplasms in female NZB/NZW mice treated with high dose cyclophosphamide. Arthritis Rheum.. 22: 1338–1343.
32.
32. White INH, DeMatteis F, Davies A, Smith LL, Crofton-Sleigh C, Venitt S, Hewer A, and Phillips DH (1992). Genotoxic potential of tamoxifen and analogues in female Fischer F-344/n rats, DBA/2 and C57BL/6 mice and in human MCL-5 cells. Carcinogenesis. 13: 2197–2203.
33.
33. Witt KL, Gulati DK, Kaur P, and Shelby MD (1995). Phenolphthalein: Induction of micronucleated erythrocytes in mice. Mutat. Res.. 341: 151–160.
34.
34. Yamamoto S, Mitsumori K, Kodama Y, Matsunuma N, Manabe S, Okamiya H, Suzuki H, Fukuda T, Sakamaki Y, Sunaga M, Nomura G, Hioki K, Wakana S, Nomura T, and Hayashi Y (1996). Rapid induction of more malignant tumors by various genotoxic carcinogens in transgenic mice harboring a human prototype c-Ha-ras gene than in control non-transgenic mice. Carcinogenesis. 17: 2455–2461.
